What influenza vaccines may be used in adults for the 2023–24 season?

Four egg-based quadrivalent standard dose IIV vaccines (SD-IIV4s), and one cell-based quadrivalent standard dose inactivated vaccine (ccIIV4), all given as intramuscular (IM) injection may be used in adults age 18 or older:

• Afluria Quadrivalent (CSL Seqirus): 0.5 mL/dose
• Fluarix Quadrivalent (GSK): 0.5 mL/dose
• FluLaval Quadrivalent (GSK): 0.5 mL/dose
• Fluzone Quadrivalent (Sanofi): 0.5 mL/dose
• Flucelvax Quadrivalent (ccIIV4, CSL Seqirus) cell-based (no egg antigen): 0.5 mL/dose (IM) for adults age 18 or older

Additional products for adults:

FluMist Quadrivalent (LAIV4, AstraZeneca): egg-based, live nasal spray vaccine: 0.2 mL (given intranasally, 0.1 mL in each nostril) for healthy, non-pregnant adults through age 49 years.

Flublok Quadrivalent (RIV4, Sanofi): recombinant, egg-free vaccine: 0.5 mL/dose (given IM) for adults age 18 or older (one of three preferred product options for adults age 65 and older).

Fluzone High-Dose Quadrivalent (egg-based HD-IIV4, Sanofi): 0.7 mL (given IM), for adults age 65 years and older (one of three preferred product options for adults age 65 and older).

Fluad Quadrivalent (egg-based aIIV4 with MF59 adjuvant, CSL Seqirus): 0.5 mL (given IM), for adults age 65 years and older (one of three preferred product options for adults age 65 and older).